Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).
The DOI matches its Crossref record.
Abstract
8536 Background: Single-agent belantamab mafodotin (B-cell maturation antigen targeting immunoconjugate) showed clinically meaningful activity and manageable safety in patients with heavily pre-treated RRMM (DREAMM-2, NCT03525678, Lancet Oncol.2020). We report updated results (median follow-up 9 months). Methods: DREAMM-2 is an ongoing single-agent belantamab mafodotin (2.5 or 3.4 mg/kg) study in patients with RRMM after ≥3 prior therapy lines and refractory to an immunomodulatory agent, a PI, and refractory and/or intolerant to an anti-CD38 mAb. Primary endpoint: overall response rate (ORR; ≥partial response per independent review committee). Results: ORR was 31% in the 2.5 mg/kg (19% with ≥very good partial responses [VGPR]) and 35% (24% with ≥VGPR) in the 3.4 mg/kg groups (Table). Duration of response (DoR) was not reached (NR) in the 2.5 mg/kg and 6.2 months in the 3.4 mg/kg groups; 1-year overall survival (OS) estimate was 53%. Common Grade 3/4 AEs ( > 10% in either group) were keratopathy (2.5: 29%; 3.5: 24%), thrombocytopenia (2.5: 21%; 3.4: 32%), anemia (2.5: 20%; 3.4: 27%), pneumonia (2.5: 6%; 3.4: 13%), and neutropenia (2.5: 11%; 3.4: 16%). AEs were managed with dose delays (2.5: 54%; 3.4: 62%) and reductions (2.5: 34%; 3.4: 43%); discontinuations due to AEs were uncommon (2.5: 9%; 3.4: 12%). Conclusions: Single-agent belantamab mafodotin was well-tolerated, and clinically meaningful responses were sustained despite dose modifications with longer follow-up. Funding: GlaxoSmithKline (205678). Drug linker technology licensed from Seattle Genetics; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa. Clinical trial information: NCT03525678 . [Table: see text]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Belantamab Mafodotin: First Approval
Markham, A. (2020) · Drugs · doi:10.1007/s40265-020-01404-x · Cited by 145
“2.3.1.1 Phase II Single agent therapy with belantamab mafodotin had promising activity in patients with relapsed or refractory multiple myeloma in the phase II DREAMM-2 study (NCT03525678) [11, 12].”
BackgroundInfluentialLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A., Callander, N., Sborov, D., Suvannasankha, A., et al. (2021) · Cancer · doi:10.1002/cncr.33809 · Cited by 144
Self-citationJagannath, S., Lin, Y., Goldschmidt, H., Reece, D., Nooka, A., Senin, A., Rodriguez-Otero, P., Powles, R., Matsue, K., Shah, N., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00507-2 · Cited by 90
Self-citationHow to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, F., Montes Gaisán, C., & de la Rubia Comos, J. (2022) · Cancers · doi:10.3390/cancers15010155 · Cited by 28
“Antibody-drug conjugate (ADC) Belantamab mafodotin (belamaf) b Bela monotherapy Adult patients with MM who have received at least four prior therapies and whose illness is refractory to PI, IMiD and anti-CD38 MoAb, and who have shown disease progression on the last therapy [43,44]”
Background
Metadata
- Authors
- Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O. A., Callander, N. S., Sborov, D. W., Suvannasankha, A., Weisel, K., Voorhees, P. M., Hoos, A., Zhi, E., Baron, J., Piontek, T., Jewell, R. C., Opalinska, J., Gupta, I., & Cohen, A. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-05-20
- Volume
- 38
- Issue
- 15_suppl
- Pages
- 8536-8536
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3030811423
- Cited by
- 27
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs). https://app.cochat.ai/papers/10.1200/jco.2020.38.15_suppl.8536
- The paper
- Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O. A., Callander, N. S., Sborov, D. W., Suvannasankha, A., Weisel, K., Voorhees, P. M., Hoos, A., Zhi, E., Baron, J., Piontek, T., Jewell, R. C., Opalinska, J., Gupta, I., & Cohen, A. D. (2020). Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2020.38.15_suppl.8536
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.